Given the political, economic and regulatory uncertainties at large, it seems pretty reasonable that Telecom Plus (TEP) is picking balance sheet strength...
There was lots of rhetoric about putting Americans first during US presidential election campaigning, but are we seeing it play out in the coal industry?...
The NHS will now offer a £90,000 breast cancer drug from Switzerland-listed pharmaceutical giant Roche, having previously considered the product to be too expensive.
Shares in bathroom fit-out specialist Norcros (NXR) look cheap despite the company delivering an eighth consecutive year of revenue growth in the 12...
BP’s (BP.) underappreciated downstream business could add 200p to the company’s current 470.35p share price if the operations were valued in line with...